DKSH and Glenmark have entered into an exclusive agreement to bring pharmaceutical and over-the-counter (OTC) products in the areas of Respiratory, Cardiovascular, and Dermatology to Cambodia.
Media release
Cambodia, Phnom Penh, October 26, 2021 – DKSH Business Unit Healthcare, Asia's leading partner for healthcare companies to grow their business in Asia and beyond, has partnered with Glenmark Pharmaceuticals Ltd, a research-led global pharmaceutical company to bring their high-quality pharmaceutical products used in respiratory, dermatology, and cardiovascular problems to Cambodian patients. The arrangement furthers DKSH's strategic direction of strengthening its regional footprint as well as expanding into the generics market.
Glenmark is a leading Indian pharmaceutical company that operates in more than 50 countries with major presence across India, US, European Union, Russia, and Brazil. As a strategic partner, DKSH Cambodia will help Glenmark grow its business, solidify their brand presence, and gain market share by managing Glenmark's distribution, and logistics as well as marketing and sales. DKSH's experienced teams and broad distribution network will ensure Glenmark's products reach modern trade, traditional trade, hospitals, clinics, other medical channels, and patients in need across the country.
Shilpa Jani, General Manager & Country Head of Glenmark, commended “We are delighted to partner with DKSH to bring our high-quality medicines to patients in Cambodia. We are confident in DKSH's strong nationwide footprint, extensive distribution network, and expertise to further strengthen Glenmark's brands and continued growth in this market.”
Sandeep Tewari, Vice President, Healthcare in Cambodia and Laos, said: “With our expertise in Market Expansion Services, we are proud to be a trusted and strategic partner for Glenmark. Our partnership demonstrates our commitment to provide patients with better health and quality of life, in line with DKSH's purpose to enrich people's lives, by providing access to healthcare, goods, services, and insights”.
For further information, please contact:
DKSH Cambodia Ltd.
Chanreasey Chum
Manager, Branding & Communications
Phone +855 23 212 838
chanreasey.chum@dksh.com
About Glenmark
Glenmark Pharmaceuticals Limited (Glenmark) is a global research-led pharmaceutical company with presence across generics, specialty, and OTC businesses and with operations in over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. It ranks among the world’s top 50 Generics and Biosimilars companies (Top 50 Company Rankings, 2020, from Informa’s Generics Bulletin). The company has been listed on the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the third consecutive year in a row. DJSI is one of the world’s most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry being featured in the index. For more information, visit www.glenmarkpharma.com
About DKSH
DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution, and logistics as well as after-sales services. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 32,450 specialists, generating net sales of CHF 10.7 billion in 2020. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 7,970 specialists, the Business Unit generated net sales of CHF 5.4 billion in 2020. www.dksh.com/hec